Neurol. praxi. 2009;10(6):353-355

Treatment of choreatic dyskinesias

doc.MUDr.Jan Roth, CSc., MUDr.Jiří Klempíř, Ph.D.
Neurologická klinika 1. LF UK a VFN, Praha

Choreatic dyskinesias are caused by the hetegenous dysfunctions of basal ganglia system. For clinical settings we have several options:

antipsychotics (i. e. risperidone, tiapride), presynaptic dopamine depletors (tetrabenazine), GABAergics (clonazepam), antiglutamatergics

(i. e. amantadine). Their intensity could be pharmacologically controlled, at least partially, however their causal curability is only

seldom available.

Keywords: chorea, antipsychotics, clonazepam, amantadine, tetrabenazine, clinical studies

Published: January 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Roth J, Klempíř J. Treatment of choreatic dyskinesias. Neurol. praxi. 2009;10(6):353-355.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Barr AN, Fischer JH, Koller WC, Spunt AL, Singhal A. Serum haloperidol concentration and choreiform movements in Huntington's disease. Neurology 1988; 38(1): 84-88. Go to original source... Go to PubMed...
    2. Biolsi B, Cif L, Fertit HE, Robles SG, Coubes P. Long-term follow-up of Huntington disease treated by bilateral deep brain stimulation of the internal globus pallidus. J Neurosurg 2008; 109(1): 130-132. Go to original source... Go to PubMed...
    3. Bonelli RM, Wenning GK. Pharmacological management of Huntington's disease: an evidence-based review. Curr Pharm Des 2006; 12(21): 2701-2720. Go to original source... Go to PubMed...
    4. Bonuccelli U, Ceravolo R, Maremmani C, Nuti A, Rossi G, Muratorio A. Clozapine in Huntington's chorea. Neurology 1994; 44(5): 821-823. Go to original source... Go to PubMed...
    5. Deroover J, Baro F, Bourguignon RP, Smets P. Tiapride versus placebo: a double-blind comparative study in the management of Huntington's chorea. Curr Med Res Opin 1984; 9(5): 329-338. Go to original source... Go to PubMed...
    6. Duff K, Beglinger LJ, O'Rourke ME, Nopoulos P, Paulson HL, Paulsen JS. Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease. Ann Clin Psychiatry 2008; 20(1): 1-3. Go to original source... Go to PubMed...
    7. Girotti F, Carella F, Scigliano G, Grassi MP, Soliveri P, Giovannini P, Parati E, Caraceni T. Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease. J Neurol Neurosurg Psychiatry 1984; 47(8): 848-852. Go to original source... Go to PubMed...
    8. Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001; 57(3): 397-404. Go to original source... Go to PubMed...
    9. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997; 48(2): 358-362. Go to original source... Go to PubMed...
    10. Kempinsky WH, Boniface WR, Morgan PP, Busch AK. Reserpine in Huntington's chorea. Neurology 1960; 10: 38-42. Go to original source... Go to PubMed...
    11. Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007; 22: 193-197. Go to original source... Go to PubMed...
    12. Kremer B, Clark CM, Almqvist EW, Raymond LA, Graf P, Jacova C, Mezei M, Hardy MA, Snow B, Martin W, Hayden MR. Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. Neurology 1999; 53(5): 1000-1100. Go to original source... Go to PubMed...
    13. Paleacu D, Anca M, Giladi N. Olanzapine in Huntington's disease. Acta Neurol Scand 2002; 105(6): 441-444. Go to original source... Go to PubMed...
    14. Parsa MA, Szigethy E, Voci JM, Meltzer HY. Risperidone in treatment of choreoathetosis of Huntington's disease. J Clin Psychopharmacol 1997; 17(2): 134-135. Go to original source... Go to PubMed...
    15. Peiris JB, Boralessa H, Lionel ND. Clonazepam in the treatment of choreiform activity. Med J Aust 1976; 1(8): 225-227. Go to original source... Go to PubMed...
    16. Roos RA, Buruma OJ, Bruyn GW, Kemp B, van der Velde EA. Tiapride in the treatment of Huntington's chorea. Acta Neurol Scand 1982; 65(1): 45-50. Go to original source... Go to PubMed...
    17. Rosas HD, Koroshetz WJ, Jenkins BG, Chen YI, Hayden DL, Beal MF, Cudkowicz ME. Riluzole therapy in Huntington's disease (HD). Mov Disord 1999; 14(2): 326-330. Go to original source... Go to PubMed...
    18. Seppi K, Mueller J, Bodner T, Brandauer E, Benke T, Weirich-Schwaiger H, Poewe W, Wenning GK. Riluzole in Huntington's disease (HD): an open label study with one year follow up. J Neurol 2001; 248(10): 866-869. Go to original source... Go to PubMed...
    19. Terrence CF. Fluphenazine decanoate in the treatment of chorea: a double-blind study. Curr Ther Res Clin Exp 1976; 20(2): 177-183. Go to PubMed...
    20. van Vugt JP, Siesling S, Vergeer M, van der Velde EA, Roos RA. Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry 1997; 63(1): 35-39. Go to original source... Go to PubMed...
    21. Verhagen Metman L, Morris MJ, Farmer C, Gillespie M, Mosby K, Wuu J, Chase TN. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 2002; 59(5): 694-699. Go to original source... Go to PubMed...
    22. Wihl G, Volkmann J, Allert N, Lehrke R, Sturm V, Freund HJ. Deep brain stimulation of the internal pallidum did not improve chorea in a patient with neuro-acanthocytosis. Mov Disord 2001; 16(3): 572-575. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.